{"id":816746,"date":"2026-06-01T18:16:03","date_gmt":"2026-06-01T18:16:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=816746"},"modified":"2026-06-01T18:16:03","modified_gmt":"2026-06-01T18:16:03","slug":"igc-pharmas-nyse-igc-ceo-appears-on-bloomberg-tv-discussing-alzheimers-fastacting-igcad1-pharmaceutical-therapeutic-more-stocks-inside","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/igc-pharmas-nyse-igc-ceo-appears-on-bloomberg-tv-discussing-alzheimers-fastacting-igcad1-pharmaceutical-therapeutic-more-stocks-inside_816746.html","title":{"rendered":"IGC Pharma\u2019s (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer\u2019s Fast-Acting IGC-AD1 Pharmaceutical Therapeutic – More Stocks Inside"},"content":{"rendered":"
\"IGC<\/a><\/div>\n

IGC Pharma, Inc. (NYSE: IGC),<\/strong> a clinical-stage AI biotechnology<\/strong> company focused on Alzheimer’s disease<\/strong>, is gaining investor attention after CEO Ram Mukunda appeared on Bloomberg TV discussing the company’s lead drug candidate, IGC-AD1, a potential fast-acting therapy for agitation associated with Alzheimer’s dementia<\/strong>.<\/p>\n

The company recently reported that enrollment in its Phase 2 CALMA clinical trial<\/strong> has reached approximately 80% of its target, marking a significant milestone as IGC advances one of its most closely watched Alzheimer’s therapeutics<\/strong> programs. The company has also expanded its clinical site network and strengthened its intellectual property portfolio, including new patents tied to its proprietary AI-powered drug discovery<\/strong> platform and IGC-AD1. Listen To Full Interview Now!<\/a><\/p>\n

Alongside IGC Pharma (NYSE: IGC<\/strong>), investors are watching Volato Group, Inc. (NYSE: SOAR<\/strong>), Abits Group Inc. (Nasdaq: ABTS<\/strong>), HUB Cyber Security Ltd. (Nasdaq: HUBC<\/strong>), Hitek Global Inc. (Nasdaq: HKIT<\/strong>), and Kartoon Studios (NYSE: TOON<\/strong>) as these smallcap<\/strong> stocks under $1<\/strong>, high-volume momentum stocks<\/strong> remain active in early trading.<\/p>\n

Beyond Alzheimer’s agitation, IGC Pharma is developing additional programs targeting amyloid plaques, neurodegenerative disease, cognitive decline, precision medicine, and neuroscience innovation<\/strong>, positioning the company at the intersection of artificial intelligence and biotechnology<\/strong>.<\/p>\n

 <\/p>\n

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Street Reports<\/a>
Contact Person:<\/strong> Editor
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.thestreetreports.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage AI biotechnology company focused on Alzheimer’s disease, is gaining investor attention after CEO Ram Mukunda appeared on Bloomberg TV discussing the company’s lead drug candidate, IGC-AD1, a potential fast-acting therapy for agitation associated … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,426,412,406,411],"tags":[],"class_list":["post-816746","post","type-post","status-publish","format-standard","hentry","category-Business","category-Financial-Market","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=816746"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=816746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=816746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=816746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}